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When should patients with
stroke receive thrombolytics?
■ EVIDENCE-BASED ANSWER
Thrombolytic therapy should be limited to
patients with acute ischemic stroke who meet
strict inclusion and exclusion criteria (Table)
and who can adhere to strict treatment protocol.
Patients treated under these conditions have
improved combined mortality and disability out-
comes at 1 year when treated with recombinant
tissue plasminogen activator (rtPA) (number
needed to treat [NNT]=18; 95% confidence
interval [CI], 11–56) (strength of recommenda-
tion [SOR]: B, meta-analysis of randomized con-
trolled trials with significant heterogeneity).1
Treating patients with rtPA outside the strict
protocols definitely increases morbidity and
mortality (SOR: A). A recent meta-analysis2 on
this topic and the Cochrane review1 of eligible
studies found the statistical heterogeneity and
lack of precision in the analyses bothersome.
These authors believed additional data were
needed to more precisely define the circum-
stances in which thrombolysis could be recom-
mended, if ever, for acute ischemic stroke.
■ EVIDENCE SUMMARY
The 2003 American Heart Association guide-
lines recommend rtPA for acute ischemic stroke
“for carefully selected patients” who also need
crucial “ancillary care.”3 The evidence for these
guidelines comes primarily from large double-
blind placebo-controlled studies using rtPA.
However, these studies—including NINDS,4
ECASS,5 and ATLANTIS6—differ in their dosing
regimen, timing, and other exclusion criteria,
and outcome measurements.
The NINDS study, often employed as a bench-
mark,3,7,8 used a slightly lower dose of rtPA than
other studies and “required that no anticoagu-
lants or antiplatelet agents be given for 24 hours
after treatment and that blood pressure be main-
tained within prespecified values.”4 Patients
were evaluated for inclusion according to strict
criteria, similar to those shown in the Table.
Patients in research studies who were treated
outside protocol guidelines, and patients treated
in community hospitals, have not fared as well as
the patients in NINDS. In Connecticut,9 a review
of thrombolysis in acute ischemic stroke revealed
protocol deviations in 67% of the patients treat-
ed. The number needed to harm (NNH) for death
was only 4 (in other words, there was an addi-
tional patient death for every 4 patients treated
with rtPA), and significant extracranial hemor-
rhage had an NNH of 8. In Cleveland,10 50% of
patients treated had at least 1 major protocol vio-
lation, and the NNH for symptomatic intracranial
hemorrhage was 6. A quality improvement pro-
gram in the Cleveland area lowered protocol vio-
lations to 19% and the NNH rose to 15.11
Improved outcomes similar to NINDS have
been noted where there are stroke units or
teams with personnel such as neurosurgeons,
strict adherence to protocols, and facilities
available to give accurate and expedient 
interventions and imaging (eg, neuroradiologic
interpretations of CTs).1 These limits restrict
the practical and safe use of rtPA to few of the
millions of stroke victims.
The net positive outcome found in the
Cochrane review1 results from subtracting the
significant increase in symptomatic intracranial
hemorrhage (NNH=16; 95% CI, 11–25) from the
larger primary decrease in disability/death
(NNT=10; 95% CI, 6–22).1 The overlapping con-
fidence intervals of the outcomes was bother-
some to the Cochrane reviewers.
■ RECOMMENDATIONS FROM OTHERS
Recommendations from the American Heart
Association,2 the American Academy of Neurology,6
Treating patients with rtPA outside
the strict protocols increases 
morbidity and mortality
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and the 6th American College of Chest Physicians
Consensus Conference on Antithrombotic Therapy7
substantially agree. With minor variations, all rec-
ommend rtPA with inclusion/exclusion criteria sim-
ilar to those outlined in the Table.
Gina Adair, MD, Joel Grant, MD, Nancy Pandhi,
MD, Robert Saunders, MD, Iris Sadowsky, DO,
Brian West, MD, J. William Kerns, MD, Shenandoah
Valley Family Practice Residency, Virginia Commonwealth
University, Front Royal; Karen Knight, MSLS, University
of Virginia, Charlottesville
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Inclusion and exclusion criteria for using 
thrombolytics for patients with acute ischemic CVA
Inclusion criteria
Patient aged 26–79 years with a diagnosis of ischemic stroke, with consistent, measurable, 
new neurologic deficit that is not clearing spontaneously and causes impairment
Onset of symptoms ≤3 hours
Informed consent obtained from patient, appropriate family member, or power of attorney
Neuroradiologist and neurosurgeon on hand
Stroke unit or equivalent team/bed available
Exclusion criteria
Major neurological deficits
Onset of symptoms >3 hours before starting treatment
Head trauma or myocardial infarction in previous 3 months
Gastrointestinal or urinary tract hemorrhage in previous 21 days
Major surgery in previous 14 days
Arterial puncture at a noncompressible site in previous 7 days
History of intracranial hemorrhage
Blood pressure >185 mm Hg systolic or >110 diastolic at time thrombolytic therapy is given
INR >1.5
On heparin, or aPTT outside normal range
Platelet count <100K mm3
Blood glucose <50 mg/dL (2.7 mmol/L)
Seizure with postictal neurological impairments
Radiologic evidence that more than one third of cerebral hemisphere (by volume) is involved
Inability to maintain adherence to treatment guidelines
(Current aspirin use is not an exclusion criterion.)
INR, international normalized ratio; aPTT, actived partial thromboplastin time
TA B L E
JFP_08.04_CI_final  7/21/04  9:25 AM  Page 658
Madden KP, Hamilton S. Recombinant tissue-type plas-
minogen activator (Alteplase) for ischemic stroke 3 to 5
hours after symptom onset. The ATLANTIS Study: a ran-
domized controlled trial. Alteplase Thrombolysis for
Acute Noninterventional Therapy in Ischemic Stroke.
JAMA 1999; 282:2019–2026.
7. Practice advisory: thrombolytic therapy for acute
ischemic stroke—summary statement. Report of the
Quality Standards Subcommittee of the American
Academy of Neurology. Neurology 1996; 47:835–839.
8. Hirsh J, Dalen J, Guyatt G; American College of Chest
Physicians. The sixth (2000) ACCP guidelines for
antithrombotic therapy for prevention and treatment of
thrombosis. American College of Chest Physicians. Chest
2001; 119(1 Suppl):1S–2S.
9. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM.
Thrombolysis for acute stroke in routine clinical prac-
tice. Arch Intern Med 2002; 162:1994–2001.
10. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type
plasminogen activator for acute ischemic stroke: the
Cleveland area experience. JAMA 2000; 283:1151–1158.
11. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam
DM; Cleveland Clinic Health System Stroke Quality
Improvement Team. Quality improvement and tissue-
type plasminogen activator for acute ischemic stroke: a
Cleveland update. Stroke 2003; 34:799–800.
■ CLINICAL COMMENTARY:
Respect the accepted inclusion and
exclusion criteria for using thrombolytics
Acute ischemic stroke has always posed the
dilemma of giving treatment that may be either
beneficial or harmful. Now the stakes of suc-
cess or failure are dramatically higher. Family
physicians must be knowledgeable about treat-
ment options, as the 3-hour window for using
rtPA after symptom onset is a diagnostic and
logistic challenge for physicians and staff. 
Our radiology colleagues help by using the
unenhanced head CT to exclude lesions that
mimic ischemic infarct and to confirm that true
stroke victims do not have identifiable infarc-
tion greater than one third of the middle cere-
bral artery territory. Clinicians involved in the
rtPA decision must know and respect fully and
without deviation the accepted inclusion and
exclusion criteria for using thrombolytics for
acute ischemic stroke, to promote recovery and
minimize death and disability due to intracra-
nial hemorrhage.
John Richmond, MD, University of Texas Southwestern
Family Practice Residency Program, Dallas
Is methylphenidate useful 
for treating adolescents 
with ADHD?
■ EVIDENCE-BASED ANSWER
Methylphenidate (Ritalin) is effective in the short-
term treatment of attention deficit/hyperactivity
disorder (ADHD) (strength of recommendation
[SOR]: A, multiple randomized control trials).
Though the immediate-release preparation is
the best studied of methylphenidate formulations,
extended-release methylphenidate (Concerta) has
similar benefits, with a dosing regimen that may
better suit an adolescent lifestyle (SOR: B, based
on extrapolation of 1 randomized controlled trial
and expert opinion).
■ EVIDENCE SUMMARY
The subjects of most ADHD medication studies
have been school-age children. Most children
with ADHD will have symptoms persisting into
teenage years, and methylphenidate has been
increasingly prescribed for them.1,2 Various 
systematic reviews and meta-analyses have
demonstrated the effectiveness of short-term
methylphenidate in the treatment of adolescents
with ADHD.3–5 Most participants in these studies
are males aged <13 years. Therefore, any conclu-
sions about the effectiveness of methylphenidate
in older adolescents must be inferred.
The most comprehensive systematic review
found 8 well-controlled crossover trials with an
average sample size of 24.8 (range, 9–48).6 The
average duration of the studies was 6 weeks.
The majority of the participants were white
males with a mean age of 13 years. Each study
showed statistically significant improvement
from treatment with methylphenidate. Average
effect sizes were calculated for 3 domains:
ADHD symptoms (0.94), social behavior (1.06),
and academic performance (1.25). Effect sizes
were calculated using a modified Cohen’s d,
which is the difference between the treated and
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